



17th NEXT GENERATION PRECISION ONCOLOGY SYMPOSIUM

SEPTEMBER 30, 2021 | LA JOLLA, CALIFORNIA

Speaker Biographies

Robert Langer, ScD

Institute Professor, Massachusetts Institute of Technology

Robert Langer is one of 12 Institute Professors at the Massachusetts Institute of Technology (MIT); being an Institute Professor is the highest honor that can be awarded to a faculty member. He has written over 1,500 articles, which have been cited nearly 350,000 times; his h-index of 292 is the highest of any engineer in history and tied for the 4th highest of any individual in any field. His patents have licensed or sublicensed to over 400 companies; he is a cofounder of a number of companies including Moderna. Dr Langer served as Chairman of the FDA's Science Board (its highest advisory board) from 1999-2002. His over 220 awards include both the United States National Medal of Science and the United States National Medal of Technology and Innovation (he is one of 3 living individuals to have received both these honors), the Charles Stark Draper Prize (often called the Engineering Nobel Prize), Queen Elizabeth Prize for Engineering, Albany Medical Center Prize, Breakthrough Prize in Life Sciences, Kyoto Prize, Wolf Prize for Chemistry, Millennium Technology Prize, Priestley Medal (highest award of the American Chemical Society), Gairdner Prize, and the Dreyfus Prize in Chemical Sciences. He holds 35 honorary doctorates and has been elected to the National Academy of Medicine, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors.

Dennis Carson, MD

Professor Emeritus of Medicine, UC San Diego

Dennis Carson, MD, the 2021 Recipient of the Duane Roth Achievement Award, has spent his career discovering new targets, and developing therapeutics, in the fields of oncology, autoimmune and infectious diseases. He developed from bench to bedside the drug cladribine (Leustatin®) for hairy cell leukemia (HCL). Developed in 1993, the breakthrough therapy for the then-fatal blood cancer, put more than 90 percent of HCL patients into long-lasting remissions. It acts like a purine nucleoside agent, which prevents cells from making DNA and RNA, and can selectively kill hairy cell leukemia cells. Heralded as a breakthrough cure, cladribine remains the first-line treatment for HCL and is also tapped as a treatment for B-cell chronic lymphocytic leukemia and multiple sclerosis. Now researchers have expanded its use to another deadly form of leukemia, drug-resistant T-cell prolymphocytic leukemia. Cladribine was a trailblazer at the time of its introduction over 20 years ago.

Dr. Carson has held leadership roles at the UCSD Stein Institute and served as Director for the UCSD Moores Cancer Center. He has founded multiple biotechnology companies in the vaccine and oncology areas. Currently, he is involved in multiple translational oncology programs that have led to new clinical trials. His recent work leading a large development project funded by California Institute for Regenerative Medicine, has brought from bench to bedside, a monoclonal antibody against cancer stem cells. At this stage in his career, he has focused his expertise and experience to help younger basic and clinical scientists in the difficult process of drug discovery and development.

Toni G. Atkins

California Senate President Pro Tempore, Senate District 39

Toni G. Atkins was born and raised in southwestern Virginia, the daughter of a miner and a seamstress, and graduated with a bachelor's degree in political science from Emory & Henry College in Emory, Va.

In 1985, she moved across the country to San Diego, California, to help care for her sister's young son while her sister served in the U.S. Navy. In San Diego, before becoming involved in public service, she worked as director of clinic services at Womancare Health Center.

Atkins served as an aide to San Diego City Councilmember and LGBT trailblazer Christine Kehoe, and, in 2000, was elected to replace Kehoe as the council's District 3 representative. During her eight-year tenure, Atkins provided steady leadership as interim Mayor of San Diego amid a challenging and tumultuous time at City Hall.

Elected by voters to the state Assembly in 2010, Atkins served there for six years. In 2014, her colleagues selected her to be the Speaker of the Assembly – she became the first San Diegan and the first lesbian to hold the position. Atkins counts a major \$7.5-billion water bond and creation of the state's first Earned Income Tax Credit among her proudest accomplishments.

In 2016, Atkins was elected to represent the 39th District in the state Senate and was appointed to the prestigious Rules Committee, in addition to the committees on Transportation and Housing, Health, Labor and Industrial Relations, and Natural Resources and Water. Among the bills she got passed and signed was SB 2, which created a permanent source of funding for affordable housing, a signature piece of legislation she had worked on for seven years.

In January 2018, after just one year in the Senate, she was elected by her colleagues to be the next Senate President pro Tempore. In March 2018, she was sworn in, becoming the first woman and the first openly LGBTQ person to lead the Legislature's upper house.

Throughout her career, Atkins has been a champion for affordable housing, the natural environment, healthcare, veterans, women, and the LGBTQ community. She lives in the South Park community of San Diego with her spouse, Jennifer, and their dog, Joey.

David Brenner, MD

Vice Chancellor, Health Sciences, UC San Diego

Dr. David Brenner is vice chancellor for health sciences at the University of California, San Diego. In this role, he leads the School of Medicine, Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California, San Diego, and UC San Diego Health.

A distinguished physician-scientist and leader in the field of gastroenterological research, Dr. Brenner first joined UC San Diego Health in 1985 as a gastroenterology fellow, later joining the School of Medicine faculty, and serving as a physician at Veterans Affairs (VA) San Diego Healthcare System.

Dr. Brenner also served as a Pew Scholar in the Biomedical Sciences and a Clinical Investigator in the VA system. In 1993, Dr. Brenner became professor and chief of the Division of Digestive Diseases and Nutrition at the University of North Carolina at Chapel Hill, where he continued to earn accolades for his patient care and research.

He was ultimately recruited to UC San Diego Health from Columbia University Medical Center College of Physicians and Surgeons, where from 2003 to 2007 he was Samuel Bard Professor and chair of the Department of Medicine, a member of the Herbert Irving Comprehensive Cancer Center, a member of the Columbia University Institute of Nutrition, and physician-in-chief of New York Presbyterian Hospital/ Columbia.

Dr. Brenner's professional memberships include the American Society for Clinical Investigation; the Association of American Physicians, for which he is currently President-Elect; the American College of Physicians; the American Gastroenterological Association, and the American Clinical and Climatological Association. He is also on the board of directors of two philanthropic foundations, the AlphaOne Foundation and the Alcoholic Beverage Medical Research Foundation. Dr. Brenner has also been published numerous times and serves on several editorial boards.

He earned his medical degree from the Yale University School of Medicine. After completing his residency at Yale-New Haven Medical Center, he served as a research associate in the Genetics and Biochemistry Branch of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH).

Yuan Chen, PhD

Professor of Surgery and Pharmacology, Chief, Division of Surgical Sciences, Department of Surgery, UC San Diego Moores Cancer Center

Yuan Chen, Ph.D., joined the UC San Diego Department of Surgery in January 2020 as a Professor in the Division of Surgical Oncology focusing on research. Dr. Chen obtained a Ph.D. in Biochemistry from Rutgers University and completed post-doctoral studies at the Scripps Research Institute. In 1994 she joined City of Hope as a faculty and was promoted to full Professor in 2005. She served on various leadership roles including the Dean of Transdisciplinary Research at the Beckman Research Institute of the City of Hope. Dr. Chen's current research interests center on the role of ubiquitin-like modifications in anti-tumor immune response and the development of therapies to target novel mechanisms to treat recalcitrant cancers like pancreatic cancer. Dr. Chen's research has been funded by the NIH, the California Institute of Regenerative Medicine, and the Pancreatic Cancer Action Network.

James Christensen, PhD

Chief Scientific Officer, EVP of Research, Mirati Therapeutics

James Christensen, PhD, is Chief Scientific Officer and Executive Vice President of Research at Mirati Therapeutics. In his role at Mirati, he is responsible for drug discovery, translational research, drug manufacturing and companion diagnostics research and teams. While at Mirati, Dr. Christensen led activities related to the discovery and advancement of the KRAS G12C inhibitor, MRTX849, as well as the spectrum-selective receptor tyrosine kinase (RTK) inhibitor, sitravatinib, through IND and clinical development. Dr. Christensen most recently was the head of Oncology Precision Medicine and member of the executive leadership team in the Oncology Research Unit at Pfizer, where he led nonclinical research for oncology programs including sunitinib (Sutent®) and crizotinib (Xalkori®).

He has authored or co-authored over 140 peer-reviewed research articles in scientific journals including *Science*, *Nature*, *Cancer Cell*, *Cancer Discovery*, *New England Journal of Medicine* and others. In addition, he also participates on the editorial boards for *Cancer Research* and *Molecular Cancer Therapeutics* and is a member of the Scientific Advisory panel at Bridge Bio/QED. Dr. Christensen received his Ph.D. degree focusing in Molecular Pharmacology from North Carolina State University with dissertation research directed toward characterization of mechanisms of apoptosis dysregulation during the process of carcinogenesis.

Ezra Cohen, MD, FRCPSC, FASCO

Chief, Division of Hematology-Oncology, Co-Director of the San Diego Center for Precision Immunotherapy, Moores Cancer Center, UC San Diego

Ezra Cohen, MD, is Chief of the Division of Hematology-Oncology, and Co-Director of the San Diego Center for Precision Immunotherapy. A physician-scientist, Dr. Cohen led an independently funded laboratory interested in mechanisms of action of novel therapeutics. He has made major contributions to targeted and immunotherapy. His research has received peer-reviewed funding in the study of epidermal growth factor receptor inhibitors, cell therapy, and immunotherapy in head and neck cancer. He has made major contributions to the understanding of critical signaling pathways, integration of novel agents into standard of care, and definition of mechanisms to overcome resistance to drug therapy. He has also recently co-developed a personalized neoantigen vaccine using unique cancer mutations to boost an anti-tumor immune response.

Dr. Cohen is the Associate Director for Clinical Science and Translational Science and leader of the Solid Tumor Therapeutics research program at Moores Cancer Center. He brings his expertise and preeminent reputation in head and neck cancer research and patient care to solid tumor therapeutics. Among other roles, he is chair of the Protocol Review and Monitoring Committee (PRMC) and serves as a member of the Cancer Council, and the Cancer Center's Executive Committee.

Dr. Cohen recently served as editor-in-chief of Oral Oncology, the highest impact specialty journal in head and neck cancer, and currently serves as senior editor for Clinical Cancer Research. He has been the principal investigator on multiple studies of novel agents in head and neck cancer and other solid tumors in all phases of development including chemoprevention, phase I, II, and III trials. Dr. Cohen has authored more than 170 papers and has presented his research at national and international meetings. In addition, he has served as a grant reviewer for the NIH, American Association for Cancer Research, American Society of Clinical Oncology, and the Ontario Institute for Cancer Research.

Dr. Cohen completed residencies in Family Medicine at the University of Toronto and in Internal Medicine at Albert Einstein College of Medicine. He completed a Hematology/Oncology fellowship at the University of Chicago where he was named chief fellow. Prior to his arrival in San Diego, Dr. Cohen was Co-Director of the Head and Neck Cancer Program, Associate Director for Education and Program Director for the Hematology/ Oncology Fellowship at the University of Chicago Comprehensive Cancer Center. A dedicated educator, Dr. Cohen also mentored and developed young faculty in his program.

Caitlin Costello, MD

Associate Clinical Professor of Medicine, Division of Blood and Marrow Transplantation, UC San Diego Moores Cancer Center

As a member of the Division of Blood and Marrow Transplantation, Dr. Costello is dedicated to providing excellent care for patients with a variety of hematologic malignancies, with a specific focus in lymphoproliferative disorders and bone marrow transplantation. Dr. Caitlin Costello's research interests focus particularly on the refinement of the management and treatment of multiple myeloma. She is dedicated to conducting clinical trials with novel agents and treatment strategies to expand the therapeutic options for patients with multiple myeloma. As we enter the age of personalized medicine, Dr. Caitlin Costello is principally interested in developing treatment strategies that are specific to the most finite genetic and molecular details of each individual patient's disease.

Dr. Costello completed a fellowship in hematology-oncology with a focus in bone marrow transplantation at UC San Diego School of Medicine. She completed a residency in internal medicine at Weill Cornell Medical College, New York-Presbyterian Hospital. Dr. Costello earned her medical degree at Tufts University School of Medicine in Boston.

Ida Deichaite, PhD

Assistant Adjunct Professor, Radiation Medicine and Applied Sciences, Director, Industry Relations, Moores Cancer Center, UC San Diego

Dr. Ida Deichaite oversees the translational aspects of oncology at UCSD Moores Cancer Center, turning innovation into commercial applications. Her successful partnering with pharma includes overseeing strategy and execution of translational alliances between academia and industry.

Dr. Deichaite is an Assistant Adjunct Professor in the Department of Radiation Medicine and Applied Sciences. Her research is focused on radiogenomics for personalizing radiation therapy to improve outcomes.

She is the Section Editor of Science Policy and Industry/Academia Interface of the Journal of Translational Medicine. Dr. Deichaite is widely published in numerous scientific journals. Dr. Deichaite received her Ph.D. from Princeton University, Master's degree from the Weismann Institute, and BA from Hebrew University.

J. Silvio Gutkind, PhD

Distinguished Professor and Chair, Department of Pharmacology, School of Medicine, Associate Director of Basic Science, Moores Cancer Center, UC San Diego

Dr. Gutkind is a Distinguished Professor and Chair, Department of Pharmacology, School of Medicine, and Associate Director for Basic Science at the Moores Cancer Center, University of California San Diego. He received his Ph.D. in pharmacy and biochemistry from the University of Buenos Aires, Argentina, and after his post-doctoral training at the NIMH and NCI, he joined the NIDCR, NIH. He served as the Chief of the Oral and Pharyngeal Cancer Branch, NIDCR, NIH, since 1998 until his recruitment to UCSD in 2015.

His research team is exploiting the emerging information on dysregulated signaling circuitries and individual genomic and molecular alterations to develop new precision therapies to prevent and treat cancer, and to identify novel multimodal strategies to enhance the response to cancer immunotherapies. As part of his translation efforts, Dr. Gutkind has led a multi institutional clinical trial establishing the benefits of treating oral cancer patients with mTOR inhibitors, and he is co-leading a new mTOR-targeting chemoprevention medicine trial in oral premalignancy. His laboratory has recently launched a new effort exploring multimodal precision immunotherapy approaches for oral cancer prevention and treatment

His honors include the NIH Merit Award, the Elliot Osserman Award from the Israel Cancer Research Foundation, the Pharmaceutical Research and Manufacturers of America (PhRMA) Research & Hope Award, the Distinguished Scientist Award from the International Association of Dental Research (IADR), and the election as the Chair, Division of Molecular Pharmacology, American Society for Pharmacology and Experimental Therapeutics (ASPET). He was elected in 2019 to the National Academy of Medicine, recognizing his team's translational efforts in the area of cancer signaling. He has published over 500 research articles in some of the most prestigious journals. He has supervised and mentored many junior investigators, who are now playing leadership roles in multiple institutions in the United States and abroad.

Robert Hollingsworth, PhD

Vice-President and Chief Scientific Officer for Cancer Vaccines and Immunotherapeutics, Pfizer

Dr. Robert Hollingsworth is the Vice-President and Chief Scientific Officer for Cancer Vaccines and Immunotherapeutics at Pfizer. He oversees research and development from target discovery through clinical proof-of-concept and is a member of Pfizer's Oncology Research and Development Leadership team.

He also is an Adjunct Assistant Professor of Oncology at Johns Hopkins School of Medicine, and has led numerous industry-academic alliances. Prior to joining Pfizer, Dr. Hollingsworth was Senior Director of Oncology Research at MedImmune where he led work to advance several cancer drugs into the clinic, including immuno-oncology antibodies and antibody-drug conjugates. He also previously served as a Director and Head of the Oncology Therapeutic Area Team at GlaxoSmithKline, where he conducted cancer genetics research and contributed the development of several small molecule cancer medicines, including Tykerb. He studied biology and physics as an undergraduate at the University of California, Berkeley, and received a Ph.D. in biochemistry, biophysics, and genetics from the University of Colorado. His post-doctoral studies elucidated the connections between cell cycle control and the function of tumor suppressor proteins.

Dr. Hollingsworth's scientific expertise includes immuno-oncology, cancer vaccines, oncolytic viruses, antibodies, and small molecule cancer drugs. He has been an invited speaker at numerous conferences, and received several prestigious awards including an American Cancer Society Fellowship and several pharma excellence awards. Dr. Hollingsworth has published many papers in top journals, including *Nature*, *Science*, and *Cancer Research*, and co-authored a seminal paper on the contribution of microenvironment factors to tumorigenesis that was named one of the top "milestones in cancer research" by *Nature*.

Catriona Jamieson, MD, PhD

Deputy Director, UC San Diego Moores Cancer Center

Catriona Jamieson, M.D., Ph.D., is Professor of Medicine in the Division of Hematology-Oncology, Deputy Director at UC San Diego Moores Cancer Center, Koman Family Presidential Endowed Chair in Cancer Research, Chief of the Division of Regenerative Medicine, Deputy Director of the Sanford Stem Cell Clinical Center, Co-Leader of the Hematologic Malignancies Program, and Director of Stem Cell Research at UC San Diego Moores Cancer Center.

Dr. Jamieson specializes in myeloproliferative disorders (MPDs) and leukemia. Myeloproliferative neoplasms are a family of uncommon but not rare degenerative disorders in which the body overproduces blood cells. Myeloproliferative neoplasms can cause many forms of blood clotting including heart attack, stroke, deep venous thrombosis, and pulmonary emboli and can develop into acute myelogenous leukemia. Although some effective treatments are available, they are laden with serious side effects. In addition, individuals can become resistant to the treatments. Dr. Jamieson studies the mutant stem cells and progenitor cells in myeloproliferative neoplasms. These cells can give rise to cancer stem cells. Cancer stem cells may lie low to evade chemotherapy and then activate again later, causing disease progression and resistance to treatment. Her goal is to find more selective, less toxic therapies.

Dr. Jamieson received her medical and doctorate degrees from the University of British Columbia. She completed her residency and clinical fellowships in bone marrow transplantation and hematology, as well as her postdoctoral research fellowship in the laboratory of Professor Irving Weissman at Stanford.

Thomas Kipps, MD, PhD

Distinguished Professor of Medicine, Evelyn and Edwin Tasch Chair in Cancer Research, Director of the Center for Novel Therapeutics, Deputy Director of Research Operations, UC San Diego Moores Cancer Center

Thomas Kipps, MD, PhD, is Distinguished Professor of Medicine, Evelyn and Edwin Tasch Chair in Cancer Research, Director of the Center for Novel Therapeutics, and Deputy Director of Research Operations at the UC San Diego's Moores Cancer Center. Dr. Kipps is a two-time awardee of a Specialized Center of Research (SCOR) in Leukemia grant from the Leukemia and Lymphoma Society, a two-time awardee of the NIH MERIT Award, and principal investigator of the CLL Research Consortium (CRC), which directed inter-institutional research among the leading investigators in CLL from across the country and abroad. Dr. Kipps is a core member of the international workshop on CLL (iwCLL) and an awardee of the Rai/Binet medal for outstanding contributions to the field of leukemia research. Dr. Kipps is the current Chair of the NCI Developmental Therapeutics Study Section and Associate Editor for *Leukemia*. He has received continuous peer-reviewed, extra-mural funding for research throughout his career and maintained a high level of research productivity.

Scott Lippman, MD

Director, Moores Cancer Center, Distinguished Professor of Medicine, Senior Associate Dean and Associate Vice Chancellor, Cancer Research and Care, UC San Diego

Scott M. Lippman, MD, is Distinguished Professor of Medicine; Director, Moores Cancer Center (MCC); Senior Associate Dean and Associate Vice Chancellor (AVC) for Cancer Research and Care; and holds the Chugai Pharmaceutical Chair at UC San Diego. He currently serves as adjunct professor at the Salk Institute for Biological Studies, Sanford Burnham Prebys Medical Discovery Institute, and MD Anderson Cancer Center (MDACC). Prior to his recruitment to MCC in 2012, he was on faculty at MDACC for 24 years, including serving as the Ellen F. Knisely Distinguished Chair and the Charles A. LeMaistre Distinguished Chair of the Departments of Clinical Cancer Prevention and Thoracic/Head and Neck Medical Oncology, respectively, for the 16 years preceding his move to MCC. He has led translational, transdisciplinary programs, notably as PI of an NCI Head and Neck (HN) Cancer SPORE, 2 PO1s and a Stand Up to Cancer (SU2C) Interception Dream Team award. His research interests include precancer biology, invasive-disease transition and cancer interception, with continuous NCI funding as a PI since 1990. Dr. Lippman was senior author of the primary report of the Erlotinib Prevention of Oral Cancer (EPOC) randomized controlled trial (RCT) (*JAMA Oncol* 2016) and follow-on reports discovering genetic drivers of immune evasion in oral precancer-invasive transition; PI of a recently reported NCI NO1 trial (*JCI Insights*, 2021); and MPI of an NCI RO1 on oral cancer signaling/prevention. He has published preliminary findings of *PD-L1* amplification and high mutational burden (in microsatellite-stable tumors) as tissue-agnostic predictive genomic biomarkers of response to immune-checkpoint blockade (ICB) in solid tumors (*JAMA Oncol*. 2018; *Cancer Immunol Res*. 2019). Most recently, he has been studying genomic predictors of ICB efficacy (germline, manuscript in prep) and was senior author of a pivotal report of genomic copy-number alteration influence on immune microenvironment in the oral precancer-invasive cancer transition and the evolution of HPV-negative (HPV-) head and neck tumorigenesis; and most importantly, discovering, extensively characterizing and validating the role of chromosome 9p loss as an essential, profound genomic driver of immune-cold tumor microenvironments in HPV- head and neck cancer (HNSC), and anti-PD-1 checkpoint-inhibitor resistance (William et al., *PNAS* 2021), which has profound implications on therapeutic and prevention clinical trial designs. He has been an invited speaker at national and international symposia and conferences, including in 2021—NCI Molecular and Cellular Characterization of Screen-Detected Lesions (MCL) Consortium, City of Hope Presidential Lectureship, 22nd Annual OSUCCC - James Scientific Meeting (ASM), FDA Mini-symposium on Cancer Prevention, 35th Aspen Cancer Conference and the 5th International Cancer Symposium organized (February, 2022) in Lyon, France. He served on the board of directors for the American Association for Cancer Research (AACR), Association of American Cancer Institutes (AACI; and program committee chair), and the Worldwide Innovative

Networking (WIN) consortium; and was founding Editor-in-Chief of the AACR journal Cancer Prevention Research, and appointed chair of the AACR cancer prevention committee by then-president Liz Blackburn. Dr. Lippman was a member of the NCI Board of Scientific Advisors Cancer Center Directors Working Group and the NIH Scientific Review Group: NCI Subcommittee A – Cancer Centers, 2016-2019. He held prior positions as: member of the FDA Oncologic Drugs Advisory Committee (ODAC), chair of the NCI CDP Prevention Study Section, member of the NCI Clinical Trials and Translational Research Advisory Committee (CTAC), chair of the SWOG cancer control research committee (and member of Scientific Advisory Board, SAB), and chair of the American Society of Clinical Oncology (ASCO) cancer prevention committee. He has published over 450 peer-reviewed primary research articles, received numerous ASCO, AACR, ACS, and other (e.g., team-science) awards and is an elected member of the Association of American Physicians (AAP) and the National Academies of Sciences, Engineering, and Medicine National Cancer Policy Forum. He was chair of the 2017 NCI Pre-Cancer Genome Atlas (PCGA) think tank; and member of the 2021 Pre-Cancer Atlas (PCA) Human Tumor Atlas Network (HTAN) and 2021 AIM-HI Women's Venture Competition (WVC) review panels (the AIM-HI Accelerator Fund's WVC is a first-of-its-kind program that provides funding, coaching and networking opportunities to women-led oncology start-ups). He has a strong track record, commitment, and passion to train the next generation of scientists and doctors (including serving as member of several PhD thesis committees), and to promote equity, diversity and inclusion in his current/ongoing roles as NCI Comprehensive MCC Director, AVC at UCSD Health System, and nationally in AIM-HI WVC.

Mike Mattie, PhD

Director of Translational Sciences and External Collaborations, Kite Pharma, a Gilead Company

Dr. Mike Mattie joined Kite in 2017 and leads a portfolio of research programs with academic collaborators and CROs aimed at strengthening the understanding of Kite products and leadership in the field of cell therapy. In addition, he leads internal bed to bench efforts to translate insights from Kite clinical trial specimens and mechanistic studies to inform Research, Clinical and Process Development efforts. Mike earned his Ph.D. from Duke University and completed postdoctoral training at the UCSF Comprehensive Cancer Center. He brings nearly two decades of pharmaceutical industry experience having worked at GlaxoSmithKline and Agensys/Astellas Pharma working on small molecule, RNA therapeutics and antibody drugs prior to joining Kite.

Aaron Miller, MD, PhD

Associate Clinical Professor, Division of Hematology and Oncology, Member of Gastrointestinal Cancer Unit, UC San Diego Moores Cancer Center

Aaron M. Miller, MD, PhD, is a board certified medical oncologist who specializes in diagnosing and treating gastrointestinal cancers. Dr. Miller's approach to care emphasizes personalized medicine/precision oncology, adoptive cellular therapy, next-generation tumor sequencing and tumor immunology. He is part of the gastrointestinal cancer unit at Moores Cancer Center at UC San Diego Health, where he works alongside a multidisciplinary team to provide patients with highly specialized care. Dr. Miller is an associate professor in the Department of Medicine, where he instructs medical students, residents and fellows at UC San Diego School of Medicine and he is actively involved in cancer research, with the aim of translating his discoveries in the lab into new ways of treating patients.

Dr. Miller completed a fellowship in hematology-oncology at UC San Diego School of Medicine, along with a residency in internal medicine. He earned his medical degree from the Feinberg School of Medicine and a doctoral degree from the Graduate School, both at Northwestern University. He is a member of numerous professional organizations, including the American Society of Clinical Oncology, the American Association for Cancer Research and the American Medical Association.

Eric Ostertag, MD, PhD

Chief Executive Officer, Poseida Therapeutics

Eric Ostertag, M.D., Ph.D., is founder and CEO of Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure. A pioneer in cell and gene therapies, Dr. Ostertag was the first graduate of the Gene Therapy Program at the University of Pennsylvania School of Medicine. He received both his Ph.D. in molecular biology and his M.D. from the University of Pennsylvania School of Medicine and his B.S. in genetics from the University of Wisconsin-Madison. From there he went on to found and lead multiple biotechnology companies, including Poseida Therapeutics in 2015 and, before that, Transposagen Biopharmaceuticals, Inc., Poseida's parent company and an early leader in the development of gene-engineering technologies. Dr. Ostertag is an inventor on more than 190 patents and patent applications and author on numerous peer-reviewed articles. He has received many scientific and clinical awards, as well as being named among The Top 50 Healthcare Technology CEOs of 2020 by The Healthcare Technology Report.

Sandip Patel, MD

Associate Professor, Co-Leader, Experimental Therapeutics, Deputy Director, San Diego Center for Precision Immunotherapy, Director, Clinical Trials Office, Moores Cancer Center, UC San Diego

Dr. Sandip Patel, MD is an Associate Professor at UCSD and a medical oncologist focused on early development of novel immunotherapy in solid tumors, in particular thoracic oncology immunotherapy trials. His lab focuses on computational immunopathology to derive spatial immune signatures that can inform novel immune target discovery.

He is co-leader for the Experimental Therapeutics (Phase 1) Program and Deputy Director for the Center for Precision Immunotherapy at UCSD. He is Director of the Clinical Trials Office at UCSD Moores Cancer Center and a member of the Cancer Immunotherapy, Experimental Therapeutics (Phase 1), and Thoracic Oncology Programs. Dr. Patel is the co-leader of the NRG Developmental Therapeutics Committee.

Dr. Patel earned his medical degree at Baylor College of Medicine, while performing research at MD Anderson Cancer Center. He completed a residency in Internal Medicine at UCLA Medical Center. He completed a fellowship in Medical Oncology and Hematology at Duke University Medical Center.

John Reed, MD, PhD

Executive Vice President, Global Head of Pharmaceutical Research & Development, Sanofi

Dr. Reed, Executive Vice President, serves as the global head of Pharmaceutical Research & Development for Sanofi, reporting to the CEO and participating as a member of the company's Executive Committee. Prior to joining Sanofi in May 2018, Dr. Reed served as global head of pharmaceutical research and early development at Roche (Basel, Switzerland) for five years (2013-2018). From 2002 to 2013, Dr. Reed served as CEO of Sanford-Burnham Medical Research Institute, La Jolla, California and ran a highly productive laboratory that generated more than 900 research publications, over 130 patents, and that was awarded more than one-hundred research grants and trained over 100 post-doctoral fellows. Dr. Reed served on multiple editorial boards of research journals. He was scientific founder or co-founder of four biotechnology companies. Dr. Reed also served on the Board of Directors for five publicly traded biopharmaceutical and biotechnology companies and on the governing boards for various non-profit biomedical research organizations. During his academic

career, Dr. Reed held faculty appointments at several universities. He is a Fellow of the American Association for the Advancement of Science (AAAS) and a recipient of numerous honors and awards for his accomplishments in biomedical research. Dr. Reed obtained his M.D. (medicine) and Ph.D. (immunology) degrees from University of Pennsylvania in 1986 (graduating Alpha Omega Alpha) and his B.A. degree (chemistry) from University of Virginia in 1980 (graduating Phi Kappa Phi). His post-graduate training included residency in Pathology & Laboratory Medicine at the Hospital of the University of Pennsylvania and a post-doctoral fellowship in Molecular Biology at Wistar Institute (Philadelphia).

Emily Rowell, PhD

Director of Translational Research, Inhibrx

Emily Rowell, Ph.D., is Director of Translation Research at Inhibrx, Inc., a San Diego-based biotechnology company focused on developing novel therapeutics by leveraging a proprietary single-domain antibody platform. A dedicated immunologist with extensive drug development expertise, Dr. Rowell is a key advisor for preclinical and clinical research, with a particular focus on clinical biomarker development and transitioning research stage programs to first-in-human clinical trials. Prior to joining Inhibrx, she was an Investigator at the Genomics Institute of the Novartis Research Foundation, leading multiple preclinical biotherapeutic programs. She received her Ph.D. from the University of Pennsylvania School of Medicine followed by a fellowship at the University of Washington School of Medicine, and has co-authored numerous studies on T cell development and function.

Robert Saddawi-Konefka, MD, PhD

Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, UC San Diego Moores Cancer Center

Dr. Saddawi-Konefka is an OHNS resident physician and postdoctoral researcher at UC San Diego. Currently, he is completing an F32-supported fellowship in the laboratory of Dr. Silvio Gutkind at the Moores Cancer Center. Dr. Saddawi-Konefka's research interests include cancer-immune dynamics and the design of translatable, precision immune-oncology therapies for head and neck cancer.

Ian Stone

Managing Director, Canale Communications

Since joining CanaleComm in 2013, Ian has provided leadership and strategic direction to numerous client accounts, with an emphasis on media relations and investor-facing communications. He has created and implemented strategic communications platforms for life science companies at virtually every stage of development, with projects that range from launching an initial corporate identity, to announcing venture rounds and clinical data, and supporting IPOs, commercial product launches and company acquisitions. Ian's work has led to client news coverage in media outlets that reach key audiences, including industry, investor, medical and mainstream publications.

Prior to joining CanaleComm in 2013, Ian served as an assistant vice president and led a San Diego office for New York-based Russo Partners. Earlier in his career, he supported communications in oncology and other disease areas for Pfizer's La Jolla Research and Development campus. Ian received a Bachelor of Arts in communications from the University of California, San Diego. Outside of work, he can often be found hiking or visiting theme parks with his wife and three children.

Bob Valamehr, PhD, MBA

Chief Research and Development Officer at Fate Therapeutics

Bob Valamehr is the Chief Research and Development Officer at Fate Therapeutics, overseeing the company's research and development activities. Previously, Dr. Valamehr has held the positions of Chief Development Officer and Vice President of Cancer Immunotherapy at Fate and prior to that played key scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center) and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer. He has co-authored numerous studies and patents related to stem cell biology, oncology and materials science. Dr. Valamehr received his Ph.D. from the Department of Molecular and Medical Pharmacology at UCLA, his M.B.A. from Pepperdine University and his B.S. from the Department of Chemistry and Biochemistry at UCLA.

Troy Wilson, PhD, JD

President & Chief Executive Officer, Kura Oncology

Troy E. Wilson, Ph.D., J.D., is one of Kura's co-founders and has served as President and Chief Executive Officer and as the chairman of our Board of Directors since Kura's inception in August 2014. Previously, Dr. Wilson served as President and Chief Executive Officer of Wellspring Biosciences, Inc., a privately-held biopharmaceutical company, and its parent company Araxes Pharma LLC from July 2012 to March 2019 and as President and Chief Executive Officer of Avidity Biosciences, Inc., a publicly-held biopharmaceutical company, from November 2012 to February 2019. Dr. Wilson served as the President and Chief Executive Officer and a member of the Board of Directors of Intellikine, Inc., a privately-held biopharmaceutical company, from April 2007 to January 2012 and from August 2007 to January 2012, respectively, until its acquisition by Takeda Pharmaceutical Company Limited. He has also been a member of the board of directors of Puma Biotechnology, Inc., a publicly-held biopharmaceutical company, since October 2013, Chairman and a member of the board of directors of Avidity Biosciences, Inc., a publicly-held biopharmaceutical company, since February 2019 and November 2012, respectively, Executive Chairman and a member of the board of directors of Wellspring Biosciences since February 2019 and July 2012, respectively, and a member of the board of managers of Araxes Pharma LLC since July 2012. Dr. Wilson holds a J.D. from New York University and graduated with a Ph.D. in bioorganic chemistry and a B.A. in biophysics from the University of California, Berkeley.